Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
All >

Deals > Western Europe

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Western Europe or involving organisations from these countries.

Total search results: 6907 | Ordered by Date (descending)
1 2 3 ... 68 69 70  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Affimed–JPMorgan Chase: investor conference, 201901 supply service Affimed presents at JP Morgan Healthcare Conference 2019 2019-01-10
Evotec–JPMorgan Chase: investor conference, 201901 supply service Evotec presents at JP Morgan Healthcare Conference 2019 2019-01-10
Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019 2019-01-10
Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019 2019-01-09
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services 2019-01-03
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing 2018-12-17
Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–NewCap: public relations, 201812 service existent by NewCap 2018-12-14
Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m 2018-12-14
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Step Pharma–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH 2018-12-10
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development 2018-12-06
Novartis–Qiagen: molecular companion diagnostics, 201812– collab devlepm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG 2018-12-05
Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA 2018-12-05
Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA 2018-12-05
CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG 2018-12-05
Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG 2018-12-05
Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH 2018-12-05
Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH 2018-12-05
Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH 2018-12-05
Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH 2018-12-05
Sillages Paris–L’Oréal: investment, 201812 acquisition of minority share by BOLD fund as inaugural investment of BOLD 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Argen-X–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argen-X: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
CRISPR Therapeutics–Barclays: investor conference, 201811 supply service CRISPR Tx presents at Barclays Gene Editing & Gene Therapy Summit 2018-11-29
Argen-X–Piper Jaffray: investor conference, 201811 supply service Argenx presents at Piper Jaffray Healthcare Conference in NYC 2018-11-28
CRISPR Therapeutics–Piper Jaffray: investor conference, 201811 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2018 2018-11-28
ABP (NL)–Optimum Strategic Communications: public relations, 201811 service existent by Optimum for Inkef Capital 2018-11-27
Argen-X–Evercore: investor conference, 201811 supply service Argenx presents at Evercore ISI HealthCONx Conference 2018 2018-11-27
Celyad–Piper Jaffray: investor conference, 201811 supply service Celyad participates at Piper Jaffray Healthcare Conference in NYC 2018-11-27
SpinDiag–SEVERAL: investment, 201811 financing round Series A €3m 2018-11-27
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development 2018-11-26
Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE 2018-11-26
Celyad–Bryan Garnier: investor conference, 201811 supply service Celyad participates at Bryan Garnier Annual Healthcare Conference in Paris 2018-11-22
Erytech–Infopro Digital: investor conference, 201811 supply service Erytech at Actionaria 2018 in Paris 2018-11-22
F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d 2018-11-22
Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases 2018-11-21
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Stilla Technologies–Alize RP: public relations, 201811 service existent PR EU by Alize RP 2018-11-20
Stilla Technologies–BNP Paribas: investment, 201811 financing round Series A totalling €16m incl co-investor BNP Paribas Développement 2018-11-20
Stilla Technologies–Idinvest Partners: investment, 201811 financing round Series A totalling €16m incl co-investor Idinvest Partners 2018-11-20
Stilla Technologies–Illumina: investment, 201811 financing round Series A totalling €16m incl lead investor Illumina Ventures 2018-11-20
Stilla Technologies–Kurma: investment, 201811 financing round Series A totalling €16m incl co-investor Kurma Partners 2018-11-20
Stilla Technologies–LBO France: investment, 201811 financing round Series A totalling €16m incl co-investor LBO France 2018-11-20
Stilla Technologies–Paris Saclay Seeds: investment, 201811 financing round Series A totalling €16m incl co-investor Paris Saclay Seeds 2018-11-20
Stilla Technologies–SEVERAL: investment, 201811 financing round Series A €16m led by Illumina Ventures 2018-11-20
Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners 2018-11-19
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Noxxon–SEVERAL: investment, 201811 capital increase €6.21m incl €4.4m from Acuitas Capital LLC 2018-11-16
Argen-X–Leucadia: investor conference, 201811 supply service Argenx presents at Jefferies 2018 London Healthcare Conference 2018-11-15
Boehringer–Epizyme: small-molecule cancer drugs, 201811– collab strategic ww to develop inhibitors toward two epigenetic targets 2018-11-15
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research 2018-11-15
I-Mab–MorphoSys: antibody cancer drug, 201811– license excl Greater China + KR for MOR210 with $3.5m upfront + $101.5m milestones + royalties 2018-11-15
Alicona–Bruker Corp: investment, 201811–201812 acquisition €na of Alicona Imaging GmbH by Bruker 2018-11-14
Argen-X–Credit Suisse: investor conference, 201811 supply service Argenx presents at Credit Suisse Annual Healthcare Conference 2018 2018-11-14
Erytech–Leucadia: investor conference, 201811 supply service Erytech at Jefferies London Healthcare Conference 2018 2018-11-14
Roivant–SEVERAL: investment, 201811 financing round $200m led by new investors NovaQuest Capital Management + RTW Investments 2018-11-13
Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19% 2018-11-12
1 2 3 ... 68 69 70  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top